This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have driven up Q1 sales.
Charles River (CRL) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
The broad-based demand and meaningful price increases in the RMS business particularly in North America are expected to have contributed to Charles River's (CRL) top line in Q4.
Hologic, Inc. (HOLX) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Hologic (HOLX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
The Zacks Analyst Blog Highlights Juniper Networks, MSCI, IDEX, Hologic and Air Products and Chemicals
by Zacks Equity Research
Juniper Networks, MSCI, IDEX, Hologic and Air Products and Chemicals are part of the Zacks top Analyst Blog.
CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
CVRx (CVRX) delivered earnings and revenue surprises of 7.27% and 5.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
STERIS (STE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS' (STE) hospital capital spending is expected to have remained robust in Q3, as evident from the healthcare backlog's recent trend.
5 S&P 500 Stocks to Buy Ahead of Earnings Next Week
by Nalak Das
Five S&P 500 companies are set to beat earnings estimates next week. These are: JNPR, MSCI, IEX, APD and HOLX.
Hologic (HOLX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed at $81.70 in the latest trading session, marking a +0.13% move from the prior day.
NextGen (NXGN) Q3 Earnings Fall Shy of Estimates, Revenues Top
by Zacks Equity Research
NextGen's (NXGN) third-quarter fiscal 2023 results reflect strength in its Recurring revenues.
Hologic (HOLX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HOLX vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
HOLX vs. EW: Which Stock Is the Better Value Option?
What's in Store for Thermo Fisher (TMO) in Q4 Earnings?
by Zacks Equity Research
The industrywide trend of record-level inflation, supply issues and staffing shortages are expected to have deterred growth in several areas of Thermo Fisher's (TMO) business in Q4.
Masimo (MASI) Expands Partnership with Philips for W1 Watch
by Zacks Equity Research
Masimo (MASI) and Royal Philips to create an open ecosystem of medical information using Masimo W1 watch and the latter???s patient monitoring ecosystem to improve home-care.
Non-COVID Diagnostics Sales to Aid Hologic (HOLX) Q1 Earnings
by Zacks Equity Research
The growing adoption of Panther instruments worldwide will likely drive Hologic's (HOLX) Q1 revenues.
Will Boston Scientific (BSX) Beat Q4 Earnings Estimates?
by Zacks Equity Research
Boston Scientific (BSX) is expected to have registered strong growth in EMEA within structural heart, including TAVR, WATCHMAN, and other interventional cardiology therapies.
Hologic (HOLX) Stock Moves -0.2%: What You Should Know
by Zacks Equity Research
In the latest trading session, Hologic (HOLX) closed at $78.76, marking a -0.2% move from the previous day.
In Search of an Earnings Beat? Play These Top 5 Stocks
by Sanghamitra Saha
These top-ranked stocks are likely to beat on bottom line in their next releases. Tap Yum China (YUMC), Impinj (PI), Five Below (FIVE), Hologic (HOLX) and Progyny (PGNY).
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
What's in Store for Abbott Laboratories (ABT) in Q4 Earnings?
by Zacks Equity Research
Within Abbott's (ABT) Established Pharmaceuticals Division (EPD), new product launches across key markets have been majorly boosting business in recent months.
Hologic (HOLX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Growing adoption of Panther instruments and growth in the Surgical business will likely drive Hologic's (HOLX) Q1 revenues.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
If You Invested $1000 in Hologic a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Hologic (HOLX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed at $79.95 in the latest trading session, marking a +0.1% move from the prior day.